FRNM

FRNM（FRNM）股票分析

$16.310

-0.569 (-3.49%)收盤時

Loading chart…
High
17.175
Open
16.400
VWAP
16.52
Vol
622.01K
Mkt Cap
—
Low
16.060
Amount
10.27M
EV/EBITDA, TTM
-0.53

Freenome, Inc. is an early cancer detection company developing blood-based screening tests to identify cancer. The Company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The Company's development of SimpleScreen CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation. SimpleScreen CRC is a colorectal cancer screening test that uses a blood sample to look for signs of cancer and certain precancerous growths. The Company's platform integrates multiomics, artificial intelligence and machine learning to uncover complex biological signals associated with cancer.

AI analysis of FRNM (FRNM)

buy

Freenome, Inc. is a good buy right now due to its recent price increase of 7.10% over the last five days and a strong analyst price target of $21, which suggests a potential upside of 42% from the current price of $14.79. Additionally, the company is set to broadly commercialize its cancer screening services, which is expected to drive revenue growth significantly.

估值指標

The current forward P/E ratio for FRNM (FRNM) is 0.00, compared to its 5-year average forward P/E of .

Forward P/E

5Y Average P/E
Current P/E
0.00

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.61
Current EV/EBITDA
-0.53
高估
-0.39
低估
-0.83

Forward P/S

Overvalued
5Y Average P/S
13.61
Current P/S
15.05
高估
14.85
低估
12.38

Whales holding FRNM

P

Perceptive Advisors LLC

+ HoldingFRNM

+26.78%

3M Return

A

Andreessen Horowitz LLC

+ HoldingFRNM

+21.50%

3M Return

R

RA Capital Management, L.P.

+ HoldingFRNM

+14.73%

3M Return

事件時間軸

2026-08-12 (ET)

09:30:00

Freenome's SimpleScreen Lung Receives FDA Breakthrough Device Designation

Show More Events

資訊

Show More News

FRNM FAQ — answered by Alphio AI

Freenome, Inc. is a good buy right now due to its recent price increase of 7.10% over the last five days and a strong analyst price target of $21, which suggests a potential upside of 42% from the current price of $14.79. Additionally, the company is set to broadly commercialize its cancer screening services, which is expected to drive revenue growth significantly.

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始